Innogene Kalbiotech




Mega Lifesciences
Concise Prescribing Info
Advanced stage head & neck cancer including nasopharyngeal carcinoma; monotherapy in high-grade astrocytoma in childn refractory to oncospecific treatment; glioblastoma multiforme in combination w/ radiation therapy in adults; patients w/ inoperable esophageal malignancy w/ epithelial origin.
Dosage/Direction for Use
IV Administer as continuous IV infusion w/in 60 min for adult or 30 min for childn & adolescent. Advanced head & neck cancer 200 mg once wkly for 6 wk in combination w/ radiotherapy &/or chemotherapy. Maintenance: 200 mg every 15 days until the patient's general condition permits. Nasopharyngeal carcinoma 200 mg once wkly for 8 wk in combination w/ radiation. Maintenance: 200 mg every 15 days until the patient's general condition permits. Inoperable esophageal malignancy w/ epithelial origin 200 mg once wkly during 6 wk concomitantly w/ standard radiotherapy &/or chemotherapy. Glioma Adult 200 mg wkly in combination w/ conventional radiation treatment. Maintenance: 200 mg every 15 days until the patient's general condition permits. Childn & adolescent Monotherapy in 2 consecutive phases: Induction phase: 150 mg/m2 wkly for 6 wk. Consolidation phase: 150 mg/m2 every 3 wk until disease progression, to be given in patient w/o progressive disease upon 8th wk of evaluation after induction.
Special Precautions
Minimize potential infusion reactions w/ diphenhydramine pretreatment especially in patients w/ history of hypersensitivity to monoclonal Ab or other medicines. History of hypersensitivity to nimotuzumab or other NSO mammalian cells derived agents; severe allergic reaction. Previous treatment w/ murine monoclonal Ab ior egf/r3. Chronic diseases in decompensated phase eg, cardiac dysfunction, DM or arterial HTN. Not recommended during pregnancy & lactation.
Adverse Reactions
Chills, fatigue, headache, nausea, pyrexia, tremors & vomiting. Potentially fatal allergic reaction including rapid & severe hypotension & urticaria.
Drug Interactions
Synergistic effects & potentiated anti-tumor activity w/ chemotherapy.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FE - EGFR (Epidermal Growth Factor Receptor) inhibitors ; Used in the treatment of cancer.
Cimaher soln for inj 50 mg/10 mL
4 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in